Objective:To investigate the effects of Hedyotis diffusa willd detoxification Spleen Prescription on tumor related index and pain in patients with advanced primary liver cancer.Methods:Eighty patients with advanced primary liver cancer admitted to our hospital during May.2014 to Dec.2015 were divided into the control group and the observation group,40 in each.The control group was treated with general supportive care,and on the base,the observation group was treated with Hedyotis diffusa willd detoxification Spleen Prescription,and supplemented syndrome treating.The VAS and the serum tumor related index levels were compared between the two groups.Results:The VAS of the two groups were all significantly reduced after treatment(P<0.05),but there was no difference between the two groups(P<0.05).And after treatment,the levels of serum Alpha fetoprotein,carcinoembryonic antigen and carbohydrate antigen 199 in the observation group were significantly lower than those in control group and before treatedment (P<0.05).After treatment,the levels of serum connective tissue growth factor and vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 alpha (HIF-1 alpha) in the observation group were significantly lower than those before treatment (P<0.05), and the observation group was significantly lower than those in control group (P<0.05).Adverse reactions of the two groups were not statistically significant (P>0.05).Conclusion:Hedyotis diffusa willd detoxification Spleen Prescription can significantly alleviate the pain of patients with advanced primary liver cancer,inhibit the proliferation of tumor cells,and there is little toxic side effects,it is safe and should be clinically widely used. |
[1] 吴孟超.原发性肝癌在中国的治疗和研究现状[J].成都医学院学报,2012,7(2):161-162.
[2] NI C Y, YANG Y,CHANG Y Q, et al.Fast-track surgery improves postoperative recovery in patients undergoing partial hepatectomy for primary liver cancer:A prospective randomized controlled trial[J].Eur J Surg Oncol,2013,39(6):542-547.
[3] JÁNOS F,GABRIELLA L.Silymarin in the prevention and treatment of liver diseases and primary liver cancer[J].Curr Pharm Biotech,2012,13(1):210-217.
[4] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-946.
[5] WANG Y,O'CONNOR M,XU Y,et al.Symptom clusters in Chinese patients with primary liver cancer[J].Oncol Nurs Forum,2012,39(6):468-79.
[6] 邓宝贵,全小明,林雪梅.加味双柏散外敷预防原发性肝癌病人围介入期肝区疼痛的疗效观察[J].护理研究,2012,26(7):613-614.
[7] 汪猛,秦凯健,杨梦琪,等.原发性肝癌的中医药诊治研究进展[J].中医药导报,2015,21(3):49-52.
[8] 何立丽,吕文良,孙桂芝.中药提取物抗原发性肝癌的研究进展[J].中华中医药杂志,2014,29(4):1175-1178.
[9] 任红艳,方肇勤.方肇勤治疗原发性肝癌撷萃[J].中国中医基础医学杂志,2014,20(1):83-83.
[10] 张欣,张国梁.血清肿瘤标记物联合检测对原发性肝癌的诊断价值[J].中国实验诊断学,2012,16(5):848-850.
[11] CHEN Q W, CHENG C S, CHEN H,et al.Effectiveness and complications of ultrasound guided fine needle aspiration for primary liver cancer in a Chinese population with serum α-fetoprotein levels ≤ 200ng/ml-a study based on 4,312 patients[J].PLoS One,2013,9(8):e101536-e101536.
[12] 刘英平,潘在兴.甲胎蛋白与癌胚抗原在原发性肝癌与转移性肝癌鉴别诊断中的意义分析[J].中国实验诊断学,2013,17(12):2269-2270.
[13] WANG L,FENG F,MA Z.Novel electrochemical redox-active species:one-step synthesis of polyaniline derivative-Au/Pd and its application for multiplexed immunoassay[J].Sci Rep,2015,19(10):3127-3145.
[14] 姚娟,黄俊星,于鸿,等.肿瘤转移相关标志物在食管鳞状细胞癌中的表达及意义[J].江苏医药,2014,40(1):31-34.
[15] 石燕,陈丽,王治宽,等.Ⅰ~Ⅲ期胃癌中VEGF、HIF-1α和TGF-β1表达的临床意义及其预后价值[J].临床肿瘤学杂志,2013,18(4):310-316. |